Who is sponsoring NCT05408858?

NCT05408858 is sponsored by Yale University.

What drugs are being tested in NCT05408858?

Interventions in NCT05408858: LGBTQ-affirmative cognitive behavioral group therapy.

What condition does NCT05408858 study?

NCT05408858 studies Anxiety Disorders, Depression, LGBTQ.

Is NCT05408858 still recruiting?

NCT05408858 is currently completed. Last updated 31 May 2024.

Are results published for NCT05408858?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-05-31 · How we verify

NCT05408858

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LGBTQ-affirmative CBT for Youth

Completed NA Results posted Last updated 31 May 2024

What this trial tests

NA trial testing LGBTQ-affirmative cognitive behavioral group therapy in Anxiety Disorders in 9 participants. Completed in 26 January 2022.

Timeline

31 August 2021

Primary endpoint
11 January 2022

26 January 2022

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	9
Start date	31 August 2021
Primary completion	11 January 2022
Estimated completion	26 January 2022
Sites	1 location across United States

Drugs / interventions tested

LGBTQ-affirmative cognitive behavioral group therapy

Conditions studied

Anxiety Disorders — all drugs for Anxiety Disorders →
Depression — all drugs for Depression →
LGBTQ — all drugs for LGBTQ →

Sponsor

Yale University

Who can join

Adults 12 to 17, any sex, with Anxiety Disorders or Depression. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Client Satisfaction With Treatment Primary · Immediate Post-treatment at Week 10

Client satisfaction with treatment will be measured through the Client Satisfaction Questionnaire-8 (CSQ-8; Larsen et al., 1979), a well-validated, 8-item self-report questionnaire designed to assess patient/client satisfaction with services received. Both the adolescent self-report and the parent report of child services versions of the CSQ-8 will be used in this study. Items are scored on a 4-point scale, where higher scores indicate more satisfaction. Total score is determined by summing the 8 items, yielding a score between 8 and 32. The CSQ-8 has demonstrated excellent internal consistenc

Group	Value	95% CI
LGBTQ-affirmative Cognitive Behavioral Group Therapy	27.13	± 5.22

Session Attendance Secondary · Immediate Post-treatment at Week 10

Participant session attendance will be tracked by the study therapist each week to examine the feasibility of weekly sessions. Attendance will be scored as an average of summed weekly attendance counts per participant.

Group	Value	95% CI
LGBTQ-affirmative Cognitive Behavioral Group Therapy	7	± 3.04

Sponsor's own description

This study will adapt LGBTQ-affirmative cognitive behavior therapy (CBT) - previously only used with adults - for youth aged 12-17 years. This intervention addresses the pathways through which minority stress compromises lesbian, gay, bisexual, transgender, and queer (LGBTQ) young peoples' mental health. The purpose of this study is to determine if the intervention is acceptable and feasible for LGBTQ youth.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anxiety Disorders

Currently open trials in the same condition.

NCT07340281 — Biomarkers for Exercise · NA · recruiting
NCT07432945 — In Vivo Exposure vs. Videochat-Based Vicarious Exposure · NA · recruiting
NCT07316374 — AI Chatbots for Anxiety Mental Health Literacy · NA · active not recruiting
NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
NCT07174947 — SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depre · Phase 2 · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05408858 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 31 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05408858.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing